Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

Leukemia volume 19, pages 1702–1704 (2005)Cite this article

TO THE EDITOR

High-dose therapy and autologous stem cell transplantation is still considered as the standard therapy for the treatment of high-risk multiple myeloma. However, immunotherapy through graft-vs-myeloma effect can be observed after reduced intensity allogeneic stem cell transplantation.1 Recently, new drugs such as antiangiogenic thalidomide and more recently proteasome inhibitor bortezomib2 have opened new directions for the treatment of multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 35: 1860–1873.

    Article  Google Scholar 

  2. Stanford BL, Zondor SD . Bortezomib treatment for multiple myeloma. Ann Pharmacother 2003; 37: 1825–1830.

    Article  CAS  Google Scholar 

  3. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–1534.

    Article  CAS  Google Scholar 

  4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  Google Scholar 

  5. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618–4625.

    Article  CAS  Google Scholar 

  6. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    Article  CAS  Google Scholar 

  7. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 12777.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Cell therapy, Hopital Saint-Antoine, AP-HP, Université Pierre et Marie Curie Paris VI, Paris, France

    E Paubelle, P Coppo, L Garderet, N-C Gorin & L Fouillard

  2. Department of radiology, Hopital Saint-Antoine, AP-HP, Paris, France

    L Azizi

  3. Department of Hemato-biology, Hopital Henri Mondor, AP-HP, Créteil, France

    D Bories

Authors
  1. E Paubelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Coppo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Garderet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Azizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Bories
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N-C Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Fouillard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Fouillard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paubelle, E., Coppo, P., Garderet, L. et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia 19, 1702–1704 (2005). https://doi.org/10.1038/sj.leu.2403855

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403855

This article is cited by

Search

Advanced search

Quick links